Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications T-Cells

Publication Date: June 18, 2021

Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy

A CD8-specific minibody PET tracer, 89Zr-Df-IAB22M2C, tracked dose- and time-dependent recruitment of human CD8+ T cells into colorectal tumors in mice treated with the GUCY2C-CD3 bispecific antibody PF-07062119. NSG mice bearing LS1034 colorectal xenografts received 2 × 10^6 activated, expanded human T cells, then PF-07062119 at 0.03 to 1 mg/kg or a non-targeted CD3 control at 1 mg/kg. Tumor uptake did not differ between doses on day 4 but rose with dose by day 9. At the highest dose, ex vivo gamma counting gave 13.0 %ID/g versus 8.0 %ID/g for the control (p = 0.026), with tumor-to-blood and tumor-to-muscle ratios of 8.6 and 27.8. Tracer uptake correlated moderately with CD8+ cell densit…

Download Now →

Author: Kevin P. Maresca, Jianqing Chen +20 more

Publications CTL Cells, DC Cells

Publication Date: May 26, 2021

Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine

Cord blood units rejected for transplantation because of their small volume supplied both the CD34+ cells and the T cells needed to make clinical-scale, non-engineered T-cell products against two leukaemia antigens, WT1 and PRAME. From eight units, CD34+ cells cultured for about five weeks with cytokines expanded roughly 7,000-fold, mostly into CD33+/CD11c+ myeloid dendritic cells. These dendritic cells, pulsed with WT1 and PRAME peptides, then stimulated the thawed CD34-negative fraction of the same unit four times, giving a mean of 1.47 × 10^8 cells per product. All six products recognised both antigens, consisted mainly of effector-memory CD4+ and CD8+ T cells with stably low exhaustio…

Download Now →

Author: Kiriakos Koukoulias, Anastasia Papadopoulou +9 more

Publications CAR T Cells G-Rex®10, G-Rex®100, G-Rex®24 Well Plate

Publication Date: May 25, 2021

Base-edited CAR T cells for combinational therapy against T cell malignancies

Base editing allowed T cells to be made resistant to T-on-T fratricide, enabling anti-CD3 and anti-CD7 CAR T cells to be produced and used together against T cell leukaemia. Primary T cells were electroporated with TRBC and CD7 guide RNAs and cytidine base editor mRNA before lentiviral 3CAR or 7CAR transduction. Co-culture of the two products yielded 97.8–99.6% TCRαβ-negative CD7-negative cells. Translocations between the edited loci were under 0.18% (T1 and T3 only) with base editing, versus 0.25–0.98% at all four junctions with Cas9. Combined 3CAR/7CAR cells lysed primary T-ALL cells and cleared CD3/CD7-positive Jurkat leukaemia in NSG mice over 31 days, but not antigen-negative tumours…

Download Now →

Author: Christos Georgiadis, Jane Rasaiyaah +5 more

Publications CAR T Cells G-Rex®10

Publication Date: May 6, 2021

Mutated GM-CSF-based CAR-T cells targeting CD116/CD131 complexes exhibit enhanced anti-tumor effects against acute myeloid leukaemia

Chimeric antigen receptor T cells that use a mutated GM-CSF ligand to target the CD116/CD131 receptor complex eliminated CD116-positive acute myeloid leukaemia cells in vitro and in mouse xenograft models. CD116 was high on 24 of 29 patient samples (83%) by relative fluorescence intensity above 2, especially in myelomonocytic and monocytic subtypes. Swapping the CH2CH3 spacer for a G4S linker improved long-term killing, and every THP-1-bearing mouse given GMR G4S CAR-T cells survived more than 145 days. The E21K ligand mutation further improved long-term in vitro activity. In MV4-11 mice, no MLL-AF4 transcripts were detected after wild-type or E21K G4S treatment. Among normal PBMC and neu…

Download Now →

Author: Aiko Hasegawa, Shoji Saito +14 more

Publications NK Cells, T-Cells, TIL Cells

Publication Date: April 13, 2021

Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy

This review compares bioreactor technologies used to expand lymphocytes for adoptive cell therapy and concludes that tailored solutions and knowledge-based process control are needed. Drawing on 117 publications meeting eligibility criteria, of which 73 had detailed expansion protocols and results, it groups them into rocking motion reactors, hollow fiber systems, alternative perfusion systems, stirred reactors, G-Rex®-based processes and Prodigy-based processes. It reports that G-Rex® processes reach expansion above 2000 fold for TIL, T cells and NK cells within 2–3 weeks, hollow fiber cultures typically give 100 to 200 fold in 1 to 2 weeks, and Prodigy cultures generally stay below 50 f…

Download Now →

Author: Oscar Fabian Garcia-Aponte, Christoph Herwig +1 more

Publications CAR T Cells

Publication Date: April 13, 2021

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma

The CARAMBA consortium built a 14-day GMP process that produces autologous SLAMF7 CAR-T cells without viral vectors for a Phase I/IIa multiple myeloma trial. CD4+ and CD8+ T cells from an unmobilized leukapheresis targeting at least 5 × 10^9 white blood cells are handled separately: activated with CD3/CD28 beads for 2 days, co-electroporated with SB100X transposase mRNA and a minicircle Sleeping Beauty transposon carrying the SLAMF7 CAR, then expanded for 12 more days in G-Rex® culture flasks with IL-2. The product is formulated at a 1:1 CD4+:CD8+ ratio and infused fresh within 48 h; it is stable for at least 72 h at 4–8 °C. Selection purity typically approaches 100%, while recoveries of…

Download Now →

Author: Sabrina Prommersberger, Michael Reiser +8 more

Publications VST Cells

Publication Date: March 31, 2021

Adoptive transfer of ex vivo expanded SARS- CoV- 2- specific cytotoxic lymphocytes: A viable strategy for COVID- 19 immunosuppressed patients?

Virus-specific T cells against SARS-CoV-2 can be expanded ex vivo from convalescent donors using a protocol originally optimized for CMV and EBV, but not from a donor never exposed to the virus. Cells from three donors were stimulated with peptide-loaded dendritic cells and then twice with peptide-loaded PHA blasts in a G-Rex® over 21 days. The asymptomatic and mildly symptomatic donors reached 1.6-fold and 1.8-fold expansion by day 14, with CD4 cells dominant at about 60% of CD3. The mildly symptomatic, antibody-positive donor gave the stronger response, while the unexposed donor's culture was stopped at day 14.

Download Now →

Author: Manuel Guerreiro, Cristóbal Aguilar-Gallardo +23 more

Publications Other

Publication Date: March 30, 2021

The Importance of Proper Oxygenation in 3D Culture

Culturing three-dimensional endocrine aggregates in standard gas-impermeable plastic produces oxygen-starved cores, and gas-permeable silicone-based static culture largely prevents this. Using finite element modeling of islets of Langerhans and stem cell-derived beta cells, the authors show that anoxia in plastic depends mainly on oxygen consumption rate and medium height, and less on seeding density. Islets are limited to roughly 3% of surface area coverage and a medium depth of about 1.3 mm. Silicone membrane culture abolished islet anoxia at densities up to about 4,400 IEQ/cm², nearly 25 times standard density. Low-temperature culture cut modeled anoxia by 20–35%, while rotational syst…

Download Now →

Author: Hubert M. Tse, Graeme Gardner +2 more

Publications CAR T Cells, NK Cells

Publication Date: March 19, 2021

Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors

Combining an oncolytic adenoviral immunotherapy encoding IL-12p70, a PD-L1 blocking mini-antibody and an HSVtk safety switch (CAdTrio) with HER2-specific CAR T-cells eradicated pancreatic adenocarcinoma tumors in mouse models. Mice bearing subcutaneous CFPAC-1 or CAPAN-1 tumors received 1 x 10^7 viral particles of CAdTrio intratumorally, followed three days later by 1 x 10^6 HER2.CARTs intravenously. In CAPAN-1 xenografts, CAR T-cells alone gave complete responses in 3 of 5 mice with relapses from HER2 loss, while the combination cured 5 of 5. Pre-treatment raised CAR T-cell infiltration at the tumor site and circulating IFN gamma. In humanized mice, the combination achieved complete resp…

Download Now →

Author: Amanda Rosewell Shaw, Caroline E. Porter +8 more

Publications CAR T Cells

Publication Date: March 3, 2021

Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells

A non-viral NKG2D CAR-T process combining piggyBac plasmid electroporation with weekly K562 feeder-cell stimulation yielded large numbers of CAR-positive T cells in 28 days. Healthy-donor PBMCs were activated with 100 ng/mL OKT3 for 2 days, electroporated with 5 µg transposase and 10 µg CAR plasmid, then expanded on irradiated K562 cells; CAR-positive cells rose from 18.4% on day 7 to 87.7% on day 28, with 58,740-fold expansion. Cryopreserved day-21 cells re-expanded after thawing, including from 60–80 mL of patient blood, and cryopreserved cells eradicated HCT-116 xenografts in mice. Weekly stimulation to day 63 preserved in vitro anti-tumor activity, and co-expressed CD20 allowed antibo…

Download Now →

Author: Johan C.K. Tay, Junjian Wang +8 more

Publications NK Cells

Publication Date: February 26, 2021

GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells

A K562-derived universal antigen presenting cell (uAPC) engineered to express CD48, 4-1BBL and membrane-bound IL-21 expanded cord blood NK cells, including CAR-transduced cells, roughly 900-fold in 14 days with purity above 97%. Research-grade NK cells expanded 903-fold by day 14, and uAPC-expanded CAR NK cells retained CAR expression above 85% and showed greater cytotoxicity against CD19-positive Raji cells than non-transduced cells. In Raji-bearing NSG mice, uAPC-expanded CAR NK cells gave better tumor control and longer survival than cells expanded with the earlier C9/IL-21 feeder. Transcriptomic analysis showed enrichment of glycolysis, oxidative phosphorylation and fatty acid metabol…

Download Now →

Author: Enli Liu, Sonny O. T. Ang +24 more

Publications NK Cells

Publication Date: February 19, 2021

RNA-Seq Analysis Reveals CCR5 as a Key Target for CRISPR Gene Editing to Regulate In Vivo NK Cell Trafficking

Ex vivo expansion of human NK cells on feeder cells reshaped their chemokine receptor program and redirected where the cells went after infusion. NK cells from healthy donors were grown for 14-16 days in G-Rex® flasks with irradiated EBV-LCL or K562.mbIL-21.41BBL feeders, then compared with freshly isolated NK cells by RNA-seq and flow cytometry. Expansion with EBV-LCL feeders upregulated 4257 genes and downregulated 7661; CXCR4 fell more than 10-fold while CCR5 rose more than 50-fold, with matching surface changes. CRISPR/Cas9 disruption of CCR5 on day 7 of culture left 26% CCR5-positive cells versus 87% in controls, and 24 h after infusion into NSG mice these cells showed less liver tra…

Download Now →

Author: Emily R. Levy, Joseph A. Clara +3 more